These cases are selected based on their likely precedential value, their importance to drug and device manufacturers, and their inherent (and subjective) merit. In this webinar, our litigators who blog for Drug and Device Law will explain the significance – whether good or bad – of each case and provide insight into how the cases will likely be influential in the future.

This program is presumptively approved for 1.5 general CLE credit in California, Illinois, New Jersey, Pennsylvania, Texas and West Virginia. For lawyers licensed in New York, this course is eligible for 1.5 credit under New York’s Approved Jurisdiction Policy. Please allow four weeks after the program to receive a certificate of attendance.